COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20140023654A1
SERIAL NO

13952997

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDIMMUNE LIMITEDCAMBRIDGE CB21 6GH

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blakey, David Charles Macclesfield, GB 18 369
BROWN, Jeffrey Lester Waltham, US 5 44
Emery, Stephen Charles Macclesfield, GB 16 342

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation